Correlations of Behavioral Deficits with Brain Pathology Assessed through Longitudinal MRI and Histopathology in the R6/2 Mouse Model of HD

PLoS ONE

Volumn 8, Issue 4, 2013, Pages

  Rattray, Ivan ^a   Smith, Edward ^a   Gale, Richard ^a   Matsumoto, Kaoru ^a   Bates, Gillian P ^a   Modo, Michel ^a,b  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b MCGOWAN INSTITUTE FOR REGENERATIVE MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HUNTINGTIN;

ABNORMAL BEHAVIOR; AGING; ANIMAL BEHAVIOR; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN ATROPHY; BRAIN LEVEL; BRAIN REGION; BRAIN SIZE; BRAIN TISSUE; CELL LOSS; CONTROLLED STUDY; CORPUS CALLOSUM; CORPUS STRIATUM; CORRELATIONAL STUDY; DISEASE COURSE; EXPERIMENTAL MOUSE; EXPLORATORY BEHAVIOR; FEMALE; HIPPOCAMPUS; HISTOPATHOLOGY; HUNTINGTON CHOREA; MALE; MOTOR CORTEX; MOTOR DYSFUNCTION; MOUSE; NEUROANATOMY; NEUROPATHOLOGY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OPEN FIELD BEHAVIOR; PASSIVE AVOIDANCE; PATHOLOGICAL ANATOMY; PHENOTYPE; PROTEIN LOCALIZATION; ROTAROD TEST; SEX DIFFERENCE; TISSUE DISTRIBUTION; VOLUMETRY;

AGE FACTORS; ANIMALS; BEHAVIOR, ANIMAL; BODY WEIGHT; BRAIN; DISEASE MODELS, ANIMAL; FEMALE; GENOTYPE; HUNTINGTON DISEASE; MAGNETIC RESONANCE IMAGING; MALE; MICE; MOTOR ACTIVITY; MUTATION; NERVE TISSUE PROTEINS; NEURONS; NUCLEAR PROTEINS; ORGAN SIZE; SEROTONIN PLASMA MEMBRANE TRANSPORT PROTEINS;

ANIMALIA; MUS;

EID: 84875940946     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0060012     Document Type: Article

References (56)

1. Tabrizi SJ, Scahill RI, Durr A, Roos RA, Leavitt BR, et al. (2011) Biological and clinical changes in premanifest and early stage Huntington's disease in the TRACK-HD study: the 12-month longitudinal analysis. Lancet Neurol 10: 31-42.
2. Stout JC, Jones R, Labuschagne I, O'Regan AM, Say MJ, et al. (2012) Evaluation of longitudinal 12 and 24 month cognitive outcomes in premanifest and early Huntington's disease. J Neurol Neurosurg Psychiatry 83(7): 687-694.
3. Delmaire C, Dumas EM, Sharman MA, van den Bogaard SJ, Valabregue R, et al. (2012) The structural correlates of functional deficits in early huntington's disease. Hum Brain Mapp. doi: 10.1002/hbm.22055.
4. Mangiarini L, Sathasivam K, Seller M, Cozens B, Harper A, et al. (1996) Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice. Cell 87: 493-506.
5. Schilling G, Becher MW, Sharp AH, Jinnah HA, Duan K, et al. (1999) Intranuclear inclusions and neuritic aggregates in transgenic mice expressing a mutant N-terminal fragment of huntingtin. Hum Mol Genet 8: 397-407.
6. Slow EJ, van Raamsdonk J, Rogers D, Coleman SH, Graham RK, et al. (2003) Selective striatal neuronal loss in a YAC128 mouse model of Huntington disease. Hum Mol Genet 12: 1555-1567.
7. Gray M, Shirasaki DI, Cepeda C, Andre VM, Wilburn B, et al. (2008) Full-length human mutant huntingtin with a stable polyglutamine repeat can elicit progressive and selective neuropathogenesis in BACHD mice. J Neurosci 28: 6182-6195.
8. Lin CH, Tallaksen-Greene S, Chien WM, Cearley JA, Jackson WS, et al. (2001) Neurological abnormalities in a knock-in mouse model of Huntington's disease. Hum Mol Genet 10: 137-144.
9. Wheeler VC, White JK, Gutekunst CA, Vrbanac V, Weaver M, et al. (2000) Long glutamine tracts cause nuclear localization of a novel form of huntingtin in medium spiny striatal neurons in HdhQ92 and HdhQ111 knock-in mice. Hum Mol Genet 9: 503-513.
10. Menalled LB, Sison JD, Wu Y, Olivieri M, Li XJ, et al. (2002) Early motor dysfunction and striosomal distribution of huntingtin microaggregates in Huntington's disease knock-in mice. J Neurosci 22: 8266-8276.
11. Woodman B, Butler R, Landles C, Lupton MK, Tse J, et al. (2007) The Hdh(Q150/Q150) knock-in mouse model of HD and the R6/2 exon 1 model develop comparable and widespread molecular phenotypes. Brain Res Bull 72: 83-97.
12. Kuhn A, Goldstein DR, Hodges A, Strand AD, Sengstag T, et al. (2007) Mutant huntingtin's effects on striatal gene expression in mice recapitulate changes observed in human Huntington's disease brain and do not differ with mutant huntingtin length or wild-type huntingtin dosage. Hum Mol Genet 16: 1845-1861.
13. Moffitt H, McPhail GD, Woodman B, Hobbs C, Bates GP, (2009) Formation of polyglutamine inclusions in a wide range of non-CNS tissues in the HdhQ150 knock-in mouse model of Huntington's disease. PLoS One 4: e8025.
14. Sathasivam K, Lane A, Legleiter J, Warley A, Woodman B, et al. (2010) Identical oligomeric and fibrillar structures captured from the brains of R6/2 and knock-in mouse models of Huntington's disease. Hum Mol Genet 19: 65-78.
15. Labbadia J, Cunliffe H, Weiss A, Katsyuba E, Sathasivam K, et al. (2011) Altered chromatin architecture underlies progressive impairment of the heat shock response in mouse models of Huntington disease. J Clin Invest 121: 3306-3319.
16. Landles C, Sathasivam K, Weiss A, Woodman B, Moffitt H, et al. (2010) Proteolysis of mutant huntingtin produces an exon 1 fragment that accumulates as an aggregated protein in neuronal nuclei in Huntington disease. J Biol Chem 285: 8808-8823.
17. Pallier PN, Drew CJ, Morton AJ, (2009) The detection and measurement of locomotor deficits in a transgenic mouse model of Huntington's disease are task- and protocol-dependent: influence of non-motor factors on locomotor function. Brain Res Bull 78: 347-355.
18. Carter RJ, Lione LA, Humby T, Mangiarini L, Mahal A, et al. (1999) Characterization of progressive motor deficits in mice transgenic for the human Huntington's disease mutation. J Neurosci 19: 3248-3257.
19. Cowin RM, Bui N, Graham D, Green JR, Grueninger S, et al. (2011) Onset and progression of behavioral and molecular phenotypes in a novel congenic R6/2 line exhibiting intergenerational CAG repeat stability. PLoS One 6: e28409.
20. Hickey MA, Gallant K, Gross GG, Levine MS, Chesselet MF, (2005) Early behavioral deficits in R6/2 mice suitable for use in preclinical drug testing. Neurobiol Dis 20: 1-11.
21. Sawiak SJ, Wood NI, Williams GB, Morton AJ, Carpenter TA, (2009) Voxel-based morphometry in the R6/2 transgenic mouse reveals differences between genotypes not seen with manual 2D morphometry. Neurobiol Dis 33: 20-27.
22. Sawiak SJ, Wood NI, Williams GB, Morton AJ, Carpenter TA, (2009) Use of magnetic resonance imaging for anatomical phenotyping of the R6/2 mouse model of Huntington's disease. Neurobiol Dis 33: 12-19.
23. Ferrante RJ, Andreassen OA, Dedeoglu A, Ferrante KL, Jenkins BG, et al. (2002) Therapeutic effects of coenzyme Q10 and remacemide in transgenic mouse models of Huntington's disease. J Neurosci 22: 1592-1599.
24. Zacharoff L, Tkac I, Song Q, Tang C, Bolan PJ, et al. (2012) Cortical metabolites as biomarkers in the R6/2 model of Huntington's disease. J Cereb Blood Flow Metab 32: 502-514.
25. Aggarwal M, Duan W, Hou Z, Rakesh N, Peng Q, et al. (2012) Spatiotemporal mapping of brain atrophy in mouse models of Huntington's disease using longitudinal in vivo magnetic resonance imaging. Neuroimage 60: 2086-2095.
26. Zhang J, Peng Q, Li Q, Jahanshad N, Hou Z, et al. (2010) Longitudinal characterization of brain atrophy of a Huntington's disease mouse model by automated morphological analyses of magnetic resonance images. Neuroimage 49: 2340-2351.
27. Simon P, Dupuis R, Costentin J, (1994) Thigmotaxis as an index of anxiety in mice. Influence of dopaminergic transmissions. Behav Brain Res 61: 59-64.
28. Filali M, Lalonde R, Rivest S, (2009) Cognitive and non-cognitive behaviors in an APPswe/PS1 bigenic model of Alzheimer's disease. Genes Brain Behav 8: 143-148.
29. Sathasivam K, Woodman B, Mahal A, Bertaux F, Wanker EE, et al. (2001) Centrosome disorganization in fibroblast cultures derived from R6/2 Huntington's disease (HD) transgenic mice and HD patients. Hum Mol Genet 10: 2425-2435.
30. Mouton PR (2011) Unbiased stereology: A consise guide. Baltimore, MD: John Hopkins University Press.
31. Sadikot AF, Sasseville R, (1997) Neurogenesis in the mammalian neostriatum and nucleus accumbens: parvalbumin-immunoreactive GABAergic interneurons. J Comp Neurol 389: 193-211.
32. Paxinos G, Franklin KBJ (2001) The mouse brain in stereotaxic coordinates. San Diego, CA: Academic Press.
33. Aziz NA, van der Burg JM, Landwehrmeyer GB, Brundin P, Stijnen T, et al. (2008) Weight loss in Huntington disease increases with higher CAG repeat number. Neurology 71: 1506-1513.
34. DiFiglia M, Sapp E, Chase KO, Davies SW, Bates GP, et al. (1997) Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain. Science 277: 1990-1993.
35. Gutekunst CA, Li SH, Yi H, Mulroy JS, Kuemmerle S, et al. (1999) Nuclear and neuropil aggregates in Huntington's disease: relationship to neuropathology. J Neurosci 19: 2522-2534.
36. Dorner JL, Miller BR, Barton SJ, Brock TJ, Rebec GV, (2007) Sex differences in behavior and striatal ascorbate release in the 140 CAG knock-in mouse model of Huntington's disease. Behav Brain Res 178: 90-97.
37. Wood NI, Carta V, Milde S, Skillings EA, McAllister CJ, et al. (2010) Responses to environmental enrichment differ with sex and genotype in a transgenic mouse model of Huntington's disease. PLoS One 5: e9077.
38. Zarringhalam K, Ka M, Kook YH, Terranova JI, Suh Y, et al. (2012) An open system for automatic home-cage behavioral analysis and its application to male and female mouse models of Huntington's disease. Behav Brain Res 229: 216-225.
39. Bode FJ, Stephan M, Suhling H, Pabst R, Straub RH, et al. (2008) Sex differences in a transgenic rat model of Huntington's disease: decreased 17beta-estradiol levels correlate with reduced numbers of DARPP32+ neurons in males. Hum Mol Genet 17: 2595-2609.
40. Stack EC, Kubilus JK, Smith K, Cormier K, Del Signore SJ, et al. (2005) Chronology of behavioral symptoms and neuropathological sequela in R6/2 Huntington's disease transgenic mice. J Comp Neurol 490: 354-370.
41. Samadi P, Boutet A, Rymar VV, Rawal K, Maheux J, et al. (2013) Relationship between BDNF expression in major striatal afferents, striatum morphology and motor behavior in the R6/2 mouse model of Huntington's disease. Genes Brain Behav 12: 108-124.
42. Klapstein GJ, Fisher RS, Zanjani H, Cepeda C, Jokel ES, et al. (2001) Electrophysiological and morphological changes in striatal spiny neurons in R6/2 Huntington's disease transgenic mice. J Neurophysiol 86: 2667-2677.
43. Ma L, Morton AJ, Nicholson LF, (2003) Microglia density decreases with age in a mouse model of Huntington's disease. Glia 43: 274-280.
44. Kusakabe M, Mangiarini L, Laywell ED, Bates GP, Yoshiki A, et al. (2001) Loss of cortical and thalamic neuronal tenascin-C expression in a transgenic mouse expressing exon 1 of the human Huntington disease gene. J Comp Neurol 430: 485-500.
45. Aylward EH, Liu D, Nopoulos PC, Ross CA, Pierson RK, et al. (2012) Striatal volume contributes to the prediction of onset of Huntington disease in incident cases. Biol Psychiatry 71: 822-828.
46. Meade CA, Deng YP, Fusco FR, Del Mar N, Hersch S, et al. (2002) Cellular localization and development of neuronal intranuclear inclusions in striatal and cortical neurons in R6/2 transgenic mice. J Comp Neurol 449: 241-269.
47. Welker KM, Patton A, (2012) Assessment of normal myelination with magnetic resonance imaging. Semin Neurol 32: 15-28.
48. Vymazal J, Klempir J, Jech R, Zidovska J, Syka M, et al. (2007) MR relaxometry in Huntington's disease: correlation between imaging, genetic and clinical parameters. J Neurol Sci 263: 20-25.
49. Jurgens CK, Jasinschi R, Ekin A, Witjes-Ane MN, Middelkoop H, et al. (2010) MRI T2 Hypointensities in basal ganglia of premanifest Huntington's disease. PLoS Curr 2.
50. Dexter DT, Jenner P, Schapira AH, Marsden CD, (1992) Alterations in levels of iron, ferritin, and other trace metals in neurodegenerative diseases affecting the basal ganglia. The Royal Kings and Queens Parkinson's Disease Research Group. Ann Neurol 32Suppl: S94-100.
51. Bartzokis G, Cummings J, Perlman S, Hance DB, Mintz J, (1999) Increased basal ganglia iron levels in Huntington disease. Arch Neurol 56: 569-574.
52. Bartzokis G, Lu PH, Tishler TA, Fong SM, Oluwadara B, et al. (2007) Myelin breakdown and iron changes in Huntington's disease: pathogenesis and treatment implications. Neurochem Res 32: 1655-1664.
53. Dumas EM, Versluis MJ, van den Bogaard SJ, van Osch MJ, Hart EP, et al. (2012) Elevated brain iron is independent from atrophy in Huntington's Disease. Neuroimage 61: 558-564.
54. Rosas HD, Chen YI, Doros G, Salat DH, Chen NK, et al. (2012) Alterations in Brain Transition Metals in Huntington Disease: An Evolving and Intricate Story. Arch Neurol 69(7): 887-893.
55. Simmons DA, Casale M, Alcon B, Pham N, Narayan N, et al. (2007) Ferritin accumulation in dystrophic microglia is an early event in the development of Huntington's disease. Glia 55: 1074-1084.
56. Murphy KP, Carter RJ, Lione LA, Mangiarini L, Mahal A, et al. (2000) Abnormal synaptic plasticity and impaired spatial cognition in mice transgenic for exon 1 of the human Huntington's disease mutation. J Neurosci 20: 5115-5123.